President and CEO of Aldeyra Therapeutics Inc (30-Year Financial, Insider Trades) Todd C Brady (insider trades) bought 20,000 shares of ALDX on 09/10/2019 at an average price of $5.14 a share. The total cost of this purchase was $102,800.
Aldeyra Therapeutics Inc is biotechnology company focused on the development of products for inflammation, inborn errors of metabolism, and other diseases, related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. Aldeyra Therapeutics Inc has a market cap of $158.575 million; its shares were traded at around $5.75 . GuruFocus has detected 1 severe warning sign with Aldeyra Therapeutics Inc. .
CEO Recent Trades:
- President and CEO Todd C Brady bought 20,000 shares of ALDX stock on 09/10/2019 at the average price of $5.14. The price of the stock has increased by 11.87% since.
CFO Recent Trades:
- CFO Joshua Reed bought 3,200 shares of ALDX stock on 09/05/2019 at the average price of $4.71. The price of the stock has increased by 22.08% since.
Directors and Officers Recent Trades:
- Director Richard Douglas bought 20,000 shares of ALDX stock on 09/10/2019 at the average price of $5. The price of the stock has increased by 15% since.
- Chief Medical Officer David J Clark bought 5,000 shares of ALDX stock on 09/06/2019 at the average price of $5.06. The price of the stock has increased by 13.64% since.
- Chief Commerical Officer David Mcmullin bought 4,329 shares of ALDX stock on 09/05/2019 at the average price of $4.68. The price of the stock has increased by 22.86% since.
For the complete insider trading history of ALDX, click here
.
